← Oncology Approval Tracker

FDA DECISION ·

Ayvakit

avapritinib · Blueprint Medicines

FDA approvalNew or expanded indicationSystemic mastocytosis
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with indolent systemic mastocytosis.

LAMPGEN ANALYSIS

Why it matters

The expansion added a targeted treatment for an indolent mast cell neoplasm, distinct from the prior advanced-disease use.

What research teams should watch

Record the mastocytosis subtype and use indication-specific dosing and platelet monitoring.

PRIMARY RECORDS

Sources